Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.

Abstract : Oral, but not transdermal, estrogen therapy increases the risk of venous thromboembolism (VTE) in women who are past menopause. Data from the Estrogen and Thromboembolism Risk (ESTHER) study were used to investigate the effects of the genetic polymorphism of NFE2L2 rs6721961, which may impair Nrf2-dependent hepatic conjugation of estrogen metabolites. As compared with nonusers, the odds ratio (OR) for VTE in current users of oral estrogens was 2.5 (95% confidence interval (CI): 1.3-4.8) in patients with wild-type NFE2L2 and 17.9 (95% CI: 3.7-85.7) in those with the polymorphism (interaction, P = 0.01).
Type de document :
Article dans une revue
Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology and Therapeutics, 2010, 89 (1), pp.60-4. 〈10.1038/clpt.2010.241〉
Liste complète des métadonnées

Littérature citée [24 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01142843
Contributeur : Pascale Sztajnbok <>
Soumis le : jeudi 16 avril 2015 - 10:08:31
Dernière modification le : vendredi 17 février 2017 - 14:30:32
Document(s) archivé(s) le : lundi 14 septembre 2015 - 09:36:42

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

Collections

Citation

Jérôme Bouligand, Odile Cabaret, Marianne Canonico, Céline Verstuyft, Liliane Dubert, et al.. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.. Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology and Therapeutics, 2010, 89 (1), pp.60-4. 〈10.1038/clpt.2010.241〉. 〈inserm-01142843〉

Partager

Métriques

Consultations de la notice

188